WO2005118813A3 - Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein - Google Patents
Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein Download PDFInfo
- Publication number
- WO2005118813A3 WO2005118813A3 PCT/EP2005/006512 EP2005006512W WO2005118813A3 WO 2005118813 A3 WO2005118813 A3 WO 2005118813A3 EP 2005006512 W EP2005006512 W EP 2005006512W WO 2005118813 A3 WO2005118813 A3 WO 2005118813A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptides
- methods
- immunogenic compositions
- expression
- nucleic acids
- Prior art date
Links
- 241000315672 SARS coronavirus Species 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05750800A EP1751178A2 (en) | 2004-06-04 | 2005-06-03 | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
CA002568838A CA2568838A1 (en) | 2004-06-04 | 2005-06-03 | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
US11/635,822 US20070190065A1 (en) | 2005-06-03 | 2006-12-04 | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86064104A | 2004-06-04 | 2004-06-04 | |
US10/860,641 | 2004-06-04 | ||
US57834804P | 2004-06-10 | 2004-06-10 | |
US60/578,348 | 2004-06-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/635,822 Continuation US20070190065A1 (en) | 2005-06-03 | 2006-12-04 | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005118813A2 WO2005118813A2 (en) | 2005-12-15 |
WO2005118813A3 true WO2005118813A3 (en) | 2006-03-16 |
Family
ID=35463454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/006512 WO2005118813A2 (en) | 2004-06-04 | 2005-06-03 | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1751178A2 (en) |
CA (1) | CA2568838A1 (en) |
WO (1) | WO2005118813A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7022969B2 (en) | 2020-02-19 | 2022-02-21 | ユーロイミューン・メディツィニシェ・ラボルディアグノシュティカ・アクチエンゲゼルシャフト | Methods and Reagents for Diagnosing SARS-CoV-2 Infections |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007010399A2 (en) * | 2005-06-28 | 2007-01-25 | HKU-PASTEUR RESEARCH CENTRE LIMITED Dexter HC Man Building | Purified trimeric s protein as vaccine against severe acute respiratory syndrome virus infections |
GB0711858D0 (en) * | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
US20160238601A1 (en) * | 2013-10-14 | 2016-08-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for coronavirus diagnostics and therapeutics |
EP4349404A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
PL3869199T3 (en) * | 2020-02-20 | 2022-05-30 | Euroimmun Medizinische Labordiagnostika Ag | A method and reagents for the diagnosis of sars-cov-2 |
WO2021186029A1 (en) * | 2020-03-20 | 2021-09-23 | Deutsches Krebsforschungszentrum | Sars spike peptides and uses thereof |
WO2021184391A1 (en) * | 2020-03-20 | 2021-09-23 | 广州市康润生物科技有限公司 | Method for earlier screening of novel coronavirus |
CA3142132C (en) * | 2020-03-30 | 2024-06-04 | Variation Biotechnologies Inc. | Vaccine compositions for the treatment of coronavirus |
WO2021223647A1 (en) * | 2020-05-06 | 2021-11-11 | The University Of Hong Kong | Compositions and methods for making and using vaccines against covid-19 |
DE20175031T1 (en) | 2020-05-15 | 2021-09-09 | Euroimmun Medizinische Labordiagnostika Ag | Method for determining the effectiveness of a SARS-CoV-2 vaccine |
CN114072422B (en) * | 2020-06-04 | 2022-06-21 | 山东博安生物技术股份有限公司 | Neutralizing antibody of SARS-CoV-2 virus and its application |
WO2021249010A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus diagnostic compositions, methods, and uses thereof |
WO2021254476A1 (en) * | 2020-06-19 | 2021-12-23 | 南京金斯瑞生物科技有限公司 | Magnetic microparticle chemiluminescence reagent kit for detecting sars-cov-2 virus neutralising antibodies and application therefor |
DE102020125915B3 (en) | 2020-10-02 | 2022-03-03 | Institut für Molekulare Diagnostik und Bioanalytik | IMMUNDIAGNOSTIC MEANS AND METHODS FOR DETECTION AND DIFFERENTIATION OF CORONAVIRUS INFECTIONS |
WO2022224271A1 (en) * | 2021-04-19 | 2022-10-27 | Bharat Serums And Vaccines Limited | Polyclonal antibodies against sars-cov-2 and implementations thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004110483A1 (en) * | 2003-05-31 | 2004-12-23 | Yiyou Chen | Method and composition of a novel vaccine design for the prevention and treatment of sars |
WO2005012360A2 (en) * | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
-
2005
- 2005-06-03 WO PCT/EP2005/006512 patent/WO2005118813A2/en active Application Filing
- 2005-06-03 CA CA002568838A patent/CA2568838A1/en not_active Abandoned
- 2005-06-03 EP EP05750800A patent/EP1751178A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004110483A1 (en) * | 2003-05-31 | 2004-12-23 | Yiyou Chen | Method and composition of a novel vaccine design for the prevention and treatment of sars |
WO2005012360A2 (en) * | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
Non-Patent Citations (7)
Title |
---|
DATABASE UniProt [online] 10 October 2003 (2003-10-10), "Spike glycoprotein precursor (Peplomer protein) (E2) [Contains: Spike protein S1; Spike protein S2].", XP002361176, retrieved from EBI accession no. UNIPROT:SPIKE_CVHSA Database accession no. SPIKE_CVHSA * |
FENG GAO ET AL: "CODON USAGE OPTIMIZATION OF HIV TYPE 1 SUBTYPE C GAG, POL, ENV, AND NEF GENES: IN VITRO EXPRESSION AND IMMUNE RESPONSES IN DNA-VACCINATED MICE", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 19, no. 9, 2003, pages 817 - 823, XP009025628, ISSN: 0889-2229 * |
GURUNATHAN S ET AL: "DNA vaccines: immunology, application, and optimization*", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, vol. 18, 2000, pages 927 - 974, XP009019110, ISSN: 0732-0582 * |
HO T-Y ET AL: "Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 4, 23 January 2004 (2004-01-23), pages 938 - 947, XP004482920, ISSN: 0006-291X * |
MARRA M A ET AL: "The genome sequence of the SARS-associated coronavirus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002269483, ISSN: 0036-8075 * |
STADLER KONRAD ET AL: "SARS - Beginning to understand a new virus", NATURE REVIEWS MICROBIOLOGY, vol. 1, no. 3, December 2003 (2003-12-01), pages 209 - 218, XP009059463, ISSN: 1740-1526 * |
ZHI Y ET AL: "Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 335, no. 1, 25 April 2005 (2005-04-25), pages 34 - 45, XP004844952, ISSN: 0042-6822 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7022969B2 (en) | 2020-02-19 | 2022-02-21 | ユーロイミューン・メディツィニシェ・ラボルディアグノシュティカ・アクチエンゲゼルシャフト | Methods and Reagents for Diagnosing SARS-CoV-2 Infections |
Also Published As
Publication number | Publication date |
---|---|
WO2005118813A2 (en) | 2005-12-15 |
EP1751178A2 (en) | 2007-02-14 |
CA2568838A1 (en) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005118813A3 (en) | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein | |
WO2006104615A3 (en) | Influenza nucleic acids, polypeptides, and uses thereof | |
WO2006002038A3 (en) | Immunostimulatory oligonucleotide multimers | |
WO2005017101A3 (en) | Avian adenoassociated virus (aaav) and uses thereof | |
WO2007050095A3 (en) | Improved vaccines and methods for using the same | |
WO2005056759A3 (en) | Methods of generating variant proteins with increased host string content and compositions thereof | |
EP1989316A4 (en) | Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions | |
WO2005003296A3 (en) | Albumin fusion proteins | |
WO2007110231A3 (en) | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES | |
WO2008028117A3 (en) | Glp-2 mimetibodies, polypeptides, compositions, methods and uses | |
WO2007067828A3 (en) | Glp-2 mimetibodies, polypeptides, compositions, methods and uses | |
EP2351843A3 (en) | Rabies virus vector systems and compositions and methods thereof | |
WO2004031210A3 (en) | Optimized multi-epitope constructs and uses thereof | |
WO2007087053A3 (en) | Bmp-7 variant compositions, methods and uses | |
WO2006047728A3 (en) | Bmp gene and fusion protein | |
WO2007045019A3 (en) | Polyoleosins | |
AU2003216184A1 (en) | Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof | |
WO2005011571A3 (en) | Hepatitis virus core proteins as vaccine platforms and methods of use thereof | |
WO2005013904A3 (en) | Sars nucleic acids, proteins, vaccines, and uses thereof | |
WO2005033265A3 (en) | Optimized multi-epitope constructs and uses thereof | |
WO2007010399A3 (en) | Purified trimeric s protein as vaccine against severe acute respiratory syndrome virus infections | |
WO2006081463A3 (en) | Thermococcus zilligii dna polymerases and variants thereof | |
WO2006073627A3 (en) | Vaccinia virus nucleic acids, polypeptides, and immunogenic compositions | |
WO2008014054A3 (en) | Bmp-7 variant compositions, methods and uses | |
EP1937717A4 (en) | Penumbra nucleic acid molecules, proteins and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2568838 Country of ref document: CA Ref document number: 7271/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11635822 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005750800 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580026090.0 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005750800 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11635822 Country of ref document: US |